Medidata Solutions, Inc. (NASDAQ:MDSO) has received a consensus recommendation of “Buy” from the fourteen research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $78.45.

A number of analysts have recently issued reports on MDSO shares. Needham & Company LLC reiterated a “buy” rating and set a $65.00 target price on shares of Medidata Solutions in a report on Wednesday, April 19th. Jefferies Group LLC upgraded Medidata Solutions from an “underperform” rating to a “hold” rating and set a $46.00 target price for the company in a report on Friday, April 28th. Morgan Stanley boosted their target price on Medidata Solutions from $63.00 to $74.00 and gave the stock an “overweight” rating in a report on Friday, April 28th. Zacks Investment Research upgraded Medidata Solutions from a “hold” rating to a “buy” rating and set a $75.00 target price for the company in a report on Wednesday, May 3rd. Finally, KeyCorp boosted their target price on Medidata Solutions from $71.00 to $74.00 and gave the stock an “overweight” rating in a report on Thursday, May 11th.

ILLEGAL ACTIVITY WARNING: “Medidata Solutions, Inc. (MDSO) Receives Average Rating of “Buy” from Analysts” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/15/medidata-solutions-inc-mdso-receives-average-rating-of-buy-from-analysts.html.

In related news, Director Robert Taylor sold 5,639 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $73.46, for a total transaction of $414,240.94. Following the transaction, the director now directly owns 54,372 shares of the company’s stock, valued at approximately $3,994,167.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.80% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC bought a new position in Medidata Solutions during the first quarter valued at approximately $121,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Medidata Solutions by 10.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,186 shares of the company’s stock valued at $171,000 after buying an additional 208 shares during the period. LS Investment Advisors LLC raised its position in Medidata Solutions by 44.6% in the first quarter. LS Investment Advisors LLC now owns 3,310 shares of the company’s stock valued at $191,000 after buying an additional 1,021 shares during the period. World Asset Management Inc bought a new position in Medidata Solutions during the first quarter valued at approximately $201,000. Finally, Miles Capital Inc. bought a new position in Medidata Solutions during the first quarter valued at approximately $202,000.

Shares of Medidata Solutions (NASDAQ:MDSO) traded down 1.35% during mid-day trading on Tuesday, hitting $73.64. 481,226 shares of the stock traded hands. The company has a market cap of $4.17 billion, a P/E ratio of 118.97 and a beta of 1.79. Medidata Solutions has a one year low of $46.10 and a one year high of $85.92. The stock has a 50 day moving average price of $77.77 and a 200-day moving average price of $66.69.

Medidata Solutions (NASDAQ:MDSO) last issued its earnings results on Tuesday, July 18th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.28 by $0.03. Medidata Solutions had a return on equity of 11.14% and a net margin of 7.07%. The business had revenue of $137.41 million during the quarter, compared to analysts’ expectations of $134.28 million. During the same quarter in the previous year, the business earned $0.24 EPS. The company’s revenue for the quarter was up 19.9% on a year-over-year basis. On average, analysts forecast that Medidata Solutions will post $1.28 earnings per share for the current fiscal year.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.